Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
EQL Pharma AB ("EQL Pharma" or the "Company") announced on 12 June 2024 that Nasdaq Stockholm's listing committee has approved that the Company's shares are admitted to trading on Nasdaq Stockholm Main Market and published a prospectus with regards to the list change on 28 June 2024. Today, on 4 July 2024, the trading in the Company's share on Nasdaq Stockholm commences.
CEO Axel Schörling comments: "The listing on Nasdaq Main Market gives us a quality stamp and is a natural step in EQL Pharma's growth story. Our current annual revenue growth rate is around 40%, and we aim to continue to be a fast-growing company for many years to come. Through the Nasdaq listing, we also gain access to international capital markets and institutional investors can become shareholders of EQL to a greater extent than before."
EQL Pharma's share will be traded in the Small Cap segment and will retain both its ticker (EQL) and ISIN code (SE0005497732). In connection with the list change, there will be no offering or issue of new shares and shareholders of EQL Pharma will not need to take any actions.
The Company has, in connection with the list change, prepared a prospectus, which is available on the Company's website, www.eqlpharma.com.
Advisors
Setterwalls Advokatbyrå AB is acting as legal advisor to EQL Pharma in connection with the listing.